Atezolizumab plus bevacizumab versus nivolumab as first‐line treatment for advanced or unresectable hepatocellular carcinoma: A cost‐effectiveness analysis
- 16 September 2022
- Vol. 128 (22), 3995-4003
- https://doi.org/10.1002/cncr.34457
Abstract
Background The cost effectiveness of atezolizumab plus bevacizumab (atezo-beva) versus nivolumab treatment for advanced or unresectable hepatocellular carcinoma is still uncertain. In this study, the cost effectiveness of these treatments was assessed in the United States. Methods A cost-effectiveness analysis integrating a network meta-analysis framework was performed using data from the IMbrave150 ( identifier NCT03434379) and CheckMate 459 ( identifier NCT02576509) trials. In total, 1244 patients were enrolled. A partitioned survival model was used to evaluate cost effectiveness. A deterministic one-way sensitivity analysis and probabilistic sensitivity analyses were further performed to evaluate model robustness. Subgroup analyses were also performed. Results Compared with the outcomes using nivolumab, the hazard ratio (HR) for overall survival with atezo-beva was 0.68 (95% CI, 0.48-0.98), and the HR for progression-free survival was 0.63 (95% CI, 0.47-0.85). Atezo-beva treatment was associated with an increase of 1.13 life-years and an increase of 0.69 quality-adjusted life-years (QALYs), as well as a $78,280 increase in cost per patient. The incremental cost-effectiveness ratio was $113,892 per QALY. The incremental net health benefit and the incremental net monetary benefit were 0.17 QALYs and $24,770, respectively, at a willingness-to-pay (WTP) threshold of $150,000 per QALY. The model was most sensitive to the HR for progression-free survival. The probability of atezo-beva being considered cost effective was 78%, and it was >50% in most of the subgroups at the WTP threshold of $150,000 per QALY. Conclusions At a WTP threshold of $150,000 per QALY and under current drug pricing, atezo-beva is likely considered cost-effective as a first-line treatment for advanced or unresectable hepatocellular carcinoma compared with nivolumab.Keywords
Funding Information
- National Natural Science Foundation of China (82160763)
This publication has 35 references indexed in Scilit:
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY ThresholdThe New England Journal of Medicine, 2014
- Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspectiveSupportive Care in Cancer, 2013
- The cost‐effectiveness of platelet additive solution to prevent allergic transfusion reactionsTransfusion, 2013
- Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysisJournal of Medical Economics, 2012
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- Out-of-Pocket Costs for Accessing Adjuvant Radiotherapy Among Canadian Women With Breast CancerJournal of Clinical Oncology, 2011
- Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United StatesJournal of Allergy and Clinical Immunology, 2011
- Economic evaluation of sorafenib in unresectable hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2010
- Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse modelLiver International, 2009
- Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochemical and Biophysical Research Communications, 2005